Cellectis S.A. (CLLS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Cellectis S.A., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Cellectis S.A. (CLLS) has returned -34.50% so far this year and 155.65% over the past 12 months. Over the last ten years, CLLS has returned -19.56% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Mar 25, 2015, CLLS's average daily return is +0.03%, while the average monthly return is +0.44%. At this rate, your investment would double in approximately 13.2 years.

Historically, 45% of months were positive and 55% were negative. The best month was Nov 2023 with a return of +207.2%, while the worst month was Mar 2020 at -41.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CLLS closed higher 47% of trading days. The best single day was Nov 1, 2023 with a return of +172.2%, while the worst single day was Oct 8, 2021 at -24.2%.

Cellectis S.A. has an annualized alpha of -8.38%, beta of 1.38, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 26, 2015.

• This stock participated in 217.23% of S&P 500 Index downside but only 126.92% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CLLS ranks 86 for risk / return — in the top 86% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Cellectis S.A. (CLLS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cellectis S.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cellectis S.A. was 97.96%, occurring on Oct 31, 2023. The portfolio has not yet recovered.

The current Cellectis S.A. drawdown is 93.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cellectis S.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cellectis S.A. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.